Perceptronix - Early Diagnosis, Better Outcomes
   
   

PMI Labs Sponsor Oral Cancer Walk with OralAdvance™

Vancouver, BC, April 15, 09 – PMI Labs (Perceptronix Medical Inc. Laboratories) are proud to announce their sponsorship of the Oral Cancer Walk NYC™ on April 18, 2009 in New York City. In addition to providing financial support for the walk, PMI Labs are donating OralAdvance™ tests to the New York University College of Dentistry/ABC Channel 7 News annual oral health screening event on April 15-17th to assess the cancerous potential of suspicious lesions detected during oral cancer screenings.

"PMI Labs are excited to be supporting the Oral Cancer Walk NYC and the NYUCD/ABC News Screening. We are delighted to provide free OralAdvance™ tests at the ABC screening event to assess any lesions detected during the screenings that may appear pre-malignant These initiatives closely parallel our efforts to raise awareness of the importance of oral cancer screening towards the early detection of oral cancer. Together we can make a real difference and save lives," comments Dr. Bojana Turic, PMI Labs President and CEO.

OralAdvance™ is used by dentists to assess the cancerous potential of suspicious lesions in the oral cavity viewed by naked eye or oral visualization device. Cells are collected from areas that look like they may be pre-cancer using OralAdvance™'s easy-to-use brush. These cells are then assessed at PMI Labs in Vancouver to determine whether they have abnormal DNA content as a result of large-scale changes indicative of cancer or pre-cancer. If early oral cancer is indicated, treatment is straight-forward and patient outcomes are favourable with the 5-year survival rate reaching 80-90%.

About OralAdvance™
With recent advances in visualization techniques for the oral cavity, dentists are encountering more suspicious lesions. OralAdvance™, with its soft cyto-brush sample collection kit, provides dentists with an informative new option for assessing these lesions before the invasive step of diagnostic biopsy. It provides an objective measure of gross DNA abnormality that can give additional information about the pre-malignant or malignant nature of a lesion.

About Perceptronix Medical Inc.
Perceptronix Medical Inc. (Vancouver, Canada) is a cancer diagnostics laboratory specializing in provision of innovative tests for the early detection of cancer based on quantitative cytology, including tests for oral cancer (www.OralAdvance.com) and lung cancer (www.LungSign.com). The Company's technology was developed in partnership with the British Columbia Cancer Agency (Vancouver, Canada). Quantitative cytology provides physicians with a cytopathology assessment based on an objective, computer-based measurement of large-scale DNA abnormality that can indicate precancerous or cancerous changes.

For further information contact:

Alexei Doudkine, PhD
Director of Business Development
Perceptronix Medical Inc.
555 West 8th Avenue, Vancouver, BC, V5Z 1C6
Phone: 604-629-8785
Email: adoudkine@perceptronix.com  
 


 

 

 

 

News and Events